Abstract:Hyperactivation of Wnt signaling is crucial in tumor formation. Fully elucidating the molecular details of how the cancer-specific Wnt signaling pathway is activated or contributes to tumorigenesis will help in determining future treatment strategies. Here, we aimed to explore the contribution of CUEDC2, a novel CUE-domain-containing protein, to the activation of Wnt signaling and the tumorigenesis of triple-negative breast cancer (TNBC) and to determine the underlying mechanisms. TNBC patient samples and disease-free survival (DFS) data were used to determine the association between CUEDC2 and TNBC progression. The effects of CUEDC2 on TNBC were examined in TNBC cells in vitro and in subcutaneous xenograft tumors in vivo. Gene knockdown, immunoprecipitation plus liquid chromatography-tandem mass spectrometry, pull-down, co-immunoprecipitation, localized surface plasmon resonance, and nuclear translocation analysis were used to uncover the mechanisms of CUEDC2 in regulating Wnt signaling and TNBC development. CUEDC2 is sufficient to maintain the hyperactivation of Wnt signaling required for TNBC tumorigenesis. The contribution of CUEDC2 plays a major role in determining the outcome of oncogenic Wnt signaling both in vitro and in vivo. Mechanistically, the CUE domain in CUEDC2 directly bound to the ARM (7-9) domain in beta-catenin, promoted beta-catenin nuclear translocation and enhanced the expression of beta-catenin targeted genes. More importantly, an 11-amino-acid competitive peptide targeting the CUE domain in CUEDC2 blocked the interactions of CUEDC2 and beta-catenin and abrogated the malignant phenotype of TNBC cells in vitro and in vivo. We observed that TNBC patients who exhibited higher levels of CUEDC2 showed marked hyperactivation of the Wnt signaling pathway and poor clinical outcomes, highlighting the clinical relevance of our findings. CUEDC2 promotes TNBC tumor growth by enhancing Wnt signaling through directly binding to beta-catenin and accelerating its nuclear translocation. Targeting the interactions of CUEDC2 and beta-catenin may be a valuable strategy for combating TNBC.

CUEDC1 Inhibits the Transcriptional Activity of AP-1 Stimulated by TNF Α

Conservative Analysis of CUEDC1 Amino Acid Sequence and CUEDC1 Inhibits Transcriptional Activity of TGF-beta/SMAD

Dysregulated Up-Frameshift Protein 1 Promotes Ulcerative Colitis Pathogenesis Through the TNFR1-NF-κB/MAPKs Pathway

Ccdc170 Affects Breast Cancer Apoptosis Through Ire1 Pathway

Transcription factor E2F1 suppresses dendritic cell maturation.

Cloning of CUEDC1 and Effect on the Transactivity Mediated by PRB and ERα

EWS Protein Inhibits the Transcriptional Activity of Nuclear Factor-κB

CUEDC2 Interacts with Estrogen Receptor β (ERβ) and Inhibits ERβ-Mediated Transactivation

CUEDC2 (CUE Domain-containing 2) and SOCS3 (suppressors of Cytokine Signaling 3) Cooperate to Negatively Regulate Janus Kinase 1/signal Transducers and Activators of Transcription 3 Signaling

Deactivation of the kinase IKK by CUEDC2 through recruitment of the phosphatase PP1

EWS Inhibits the Transcriptional Activity of IRF3 Stimulated with TRIF and IKKε

The novel secretory protein CGREF1 inhibits the activation of AP-1 transcriptional activity and cell proliferation

CUEDC2 Drives -Catenin Nuclear Translocation and Promotes Triple-Negative Breast Cancer Tumorigenesis

The interaction of KCTD1 with transcription factor AP-2alpha inhibits its transactivation.

Positive and Negative Modulation of the Transcriptional Activity of the ETS Factor ESE-1 through Interaction with p300, CREB-binding Protein, and Ku 70/86

Coiled-coil Domain Containing 3 (CCDC3) Represses Tumor Necrosis Factor-Α/nuclear Factor Κb-Induced Endothelial Inflammation.

The Inhibition of TNFα-induced NF-κB Transcriptional Activity by AWP1

Derepression of the C/EBPα Gene During Adipogenesis: Identification of AP-2α As a Repressor

Repression of Transcription Mediated by Dual Elements in the CCAAT/enhancer Binding Protein Α Gene

CCDC134 Facilitates T Cell Activation Through the Regulation of Early T Cell Receptor Signaling.

Costimulation of cAMP and Protein Kinase C Pathways Inhibits the CD3-Dependent T Cell Activation and Leads to a Persistent Expression of the AP-1 Transcription Factor